RxDoctor Payments Data

Kenneth Chan, MD

Internal Medicine · San Gabriel, CANPI 1861422370

Payments from drug & device makers

$1,740in general payments, 2019–2025

Across 66 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$356
  • Bayer$228
  • Phathom Pharmaceuticals, Inc.$208
  • Gilead$194
  • Novo Nordisk$116
  • Novartis$88
  • plus $549 from 14 others

What the payments were for

  • Food & beverage$1,740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,740 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$56,754
Medicare patients
171
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin69$68,067
ProliaDenosumab37$60,547
JanuviaSitagliptin Phosphate33$35,999
FarxigaDapagliflozin Propanediol32$28,585
VascepaIcosapent Ethyl17$11,586
TradjentaLinagliptin17$11,563
LinzessLinaclotide18$10,059
Losartan Potassium343$3,827
Atorvastatin Calcium301$3,308
Icosapent Ethyl14$3,261
Nifedipine ErNifedipine136$3,156
Metformin Hcl192$2,642
Diclofenac Sodium15$2,365
Amlodipine Besylate288$1,904
Doxazosin Mesylate103$1,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$36$79,63086 claims
AmgenProlia$63$60,54737 claims
MerckJanuvia$20$35,99933 claims
AstraZenecaFarxiga$356$28,58532 claims
AbbVieLinzess$66$10,05918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Gabriel

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →